Drug Overdose and Antidotes

Drug overdose refers to a situation in which the level of a substance in the body surpasses normal metabolism and results in harmful or life-threatening effects. Overdose may be intentional, taken for purposes of self-harm or to augment euphoria, or unintentional, such as when an individual underestimates the appropriate dose of a medication, accidentally combines two medications with opposing physiological actions, or encounters an adulterant in the illicit drug supply. The definition is straightforward, but the clinical picture can be more complex: overdoses may occur acutely or insidiously over several hours, and they may include prescription medications, over-the-counter (OTC) medications, illicit drugs, or some combination thereof.

Clinicians classify the clinical effects of overdose using toxidromes, or groups of signs and symptoms that are commonly seen with particular classes of drugs. Examples of common toxidromes include the opioid toxidrome (pinpoint pupils, bradypnea, decreased level of consciousness), the stimulant toxidrome (agitation, hypertension, tachycardia, hyperthermia), and the anticholinergic toxidrome (dry skin, mydriasis, delirium). Recognition of these patterns helps nurses to form an initial clinical impression, especially in cases where the substance is unknown (Amaducci et al., 2023; Delaney et al., 2022; Nadal-Gratacós et al., 2024; Stangeland et al., 2025).

In the current drug environment, however, toxidromes may be mixed or changing. A patient who uses fentanyl and methamphetamine together, for example, may cycle between agitation and somnolence, making it difficult to know which agent is predominant. This added complexity underscores the need for ongoing education and real-time consultation with poison control and pharmacy resources (Delaney et al., 2022; Stangeland et al., 2025).

Supportive Care: The Foundation of Treatment

In some cases of poisoning, patients will do well with good supportive care alone, even before a specific antidote or mechanism is suspected or confirmed. Supportive care generally includes optimizing airway management, hemodynamic stability, temperature, and controlling seizures or agitation (Kariisa et al., 2023; Stangeland et al., 2025).

Gastrointestinal Decontamination

The goal of decontamination is to prevent further gastrointestinal absorption of the poison. All gastrointestinal decontamination interventions are time-sensitive and should be considered only if the potential benefit outweighs the risk. Syrup of ipecac is no longer recommended for home use and, even in the ED, is contraindicated because it delays definitive decontamination and increases aspiration risk.

Activated Charcoal

• Best if administered within 1 hour of ingestion.
• Usual dose: 1 gram (G)/kg (maximum of 50 G) by mouth or nasogastric (NG) tube.
• Contraindications: unprotected airway, caustic ingestion or known corrosive ingestion, hydrocarbon ingestion, bowel obstruction.
• Charcoal adsorbs many but not all toxins. Activated charcoal will not adsorb iron, lithium, alcohols, heavy metals, or corrosives.
• Assess for vomiting and aspiration risk.

Gastric Lavage ("Pumping the Stomach")

• Exceptionally rare, but maybe performed if ingestion was less than 60 minutes ago, the substance is life-threatening and expected to cause death without decontamination, and no safer alternative is available.
• Always intubate and protect the airway before lavage. Risk: aspiration, esophageal, or gastric injury.
• Give only on a physician's orders with suction ready and healthcare personnel in PPE.

Whole Bowel Irrigation (WBI)

• Indicated for sustained-release medications, iron, lithium, or "body packers"/"suitcase" cases.
• Administer polyethylene glycol solution, usually at 1.5–2 L/hour for adults, until effluent is clear.
• Must have intact bowel function; monitor closely for dehydration.
• Do NOT induce vomiting.

Ideally, we would know the poison definitively before starting antidote therapy. However, some antidotes are extremely time-critical and cannot wait for the results of drug testing. It is not uncommon for providers to prepare and administer the antidote based on clinical suspicion alone, using either a clinical protocol or with Poison Control consultation and guidance (Kariisa et al., 2023; Stangeland et al., 2025).

Enhanced Elimination

Mechanisms to enhance the elimination of certain poisons are available:

• Urinary alkalinization (administering sodium bicarbonate) promotes the excretion of salicylates and phenobarbital.
• Hemodialysis is a way to rapidly remove toxins with low molecular weight and low protein binding (e.g., lithium, methanol, ethylene glycol, salicylates).
• Multiple-dose activated charcoal may disrupt enterohepatic circulation, leading to enhanced elimination of carbamazepine, theophylline, or phenobarbital.

Providers will coordinate labs, assess acid-base balance, and consult dialysis staff to prevent adverse effects.

Observation and Reassessment

Symptoms will change as toxins are absorbed and metabolized. Nurses should recheck vital signs, neurologic status, and cardiac rhythm at least every 15 minutes in unstable patients. Chart subtle changes that may indicate worsening, such as new tremors, rising temperature, or altered pupils.

Rebound sedation after naloxone or delayed hepatic failure after acetaminophen ingestion are classic examples of delayed decompensation that can be missed without close monitoring (Amaducci et al., 2023; Kariisa et al., 2023).

Coordination with Poison Control and the Healthcare Team

Call Poison Control (1-800-222-1222) for every patient who has been poisoned. Include:

• Substance (if known), amount, and route
• Time of exposure
• Patient's weight, age, and symptoms
• Interventions already performed

Poison Control will provide immediate, case-specific recommendations, monitor regional patterns and epidemiologic data, and help determine the appropriate observation period, lab panels, and need for transfer.

Healthcare professionals serve as liaisons and communicators and must ensure recommendations are passed on accurately and promptly.

Preventing Secondary Harm

While performing the above interventions, it is important to anticipate future needs:

• Protect the airway before administering oral therapies.
• Avoid unproven or unsupported interventions (ipecac, forced diuresis).
• Prevent hypothermia during decontamination with warm blankets and fluids.
• Label and save vomitus, pill fragments, and containers for forensic/clinical analysis.
• Address the patient's emotional needs; agitation, fear, and shame are common after overdose.

Key points to remember include the following (Kariisa et al., 2023; Stangeland et al., 2025):

• Time is brain tissue: treat emergently, diagnose subsequently.
• Supportive care (airway, breathing, circulation, seizure control) is resuscitative care that is the primary intervention in the majority of poisoned patients.
• Activated charcoal is the preferred agent for gastrointestinal decontamination early in the course of poisoning; ipecac and gastric lavage are no longer recommended in most instances.
• Empiric antidotes may be lifesaving; when suspicion is high, treatment should not be delayed while awaiting laboratory results.
• Reassessment at frequent intervals is crucial; the clinical picture of toxicity will change with time.
• Consultation with Poison Control should occur early in the course of management.
• Documentation of a thorough assessment and communication of management are important to ensure follow-up care and avoid medical errors.
• Compassion is therapeutic: providing nonjudgmental care will yield better patient outcomes.

As stated before, the term toxidrome refers to a predictable, characteristic constellation of signs and symptoms associated with a specific class of substances. When common toxidromes are recognized, providers can quickly and effectively assess patients with suspected overdoses and begin treatment based on evidence and sound clinical reasoning, even before laboratory data become available. In the ED or prehospital setting, toxidrome recognition may be the deciding factor in whether a patient receives potentially lifesaving antidotes and supportive care or simply non-specific decontamination (Kariisa et al., 2023; Delaney et al., 2022; Stangeland et al., 2025).

Because poly-substance use is common, toxidromes are seldom "textbook perfect." However, classic presentations do provide a helpful foundation for pattern recognition in patients with mixed overdoses, just as ECG interpretation starts with the ability to recognize the major rhythm families (Delaney et al., 2022; Stangeland et al., 2025).

Opioid toxicity is one of the most common and deadly toxidromes. Opioids exert their effects through mu (μ), kappa (κ), and delta (δ) receptors. Activation of these receptors blunts the brain's respiratory drive, slows gastrointestinal motility, and suppresses CNS function. Common agents include fentanyl, heroin, morphine, oxycodone, hydrocodone, methadone, and synthetic opioids like nitazenes (Amaducci et al., 2023; Delaney et al., 2022; Edinoff et al., 2023; Stangeland et al., 2025).

Clinical presentation and system findings include:

• Neurologic: Depressed LOC, stupor, unresponsiveness
• Respiratory: Bradypnea (< 8/min), shallow respirations, apnea
• Pupils: Pinpoint (miosis), minimal reactivity
• Cardiac: Bradycardia, hypotension
• Skin: Cool, clammy, possible cyanosis
• Gastrointestinal/Other: Decreased bowel sounds, urinary retention
• Classic triad: Miosis + respiratory depression + altered mental status

All of these toxidromes have CNS depression and respiratory depression similar to opioids, but have distinct differences in pupils, vital signs, and antidote availability (Amaducci et al., 2023; Delaney et al., 2022; Kariisa et al., 2023; Stangeland et al., 2025).

This includes opioids, benzodiazepines, barbiturates, alcohol/toxic alcohol, and clonidine (Amaducci et al., 2023; Gallo & Hulse, 2021; NIDA, 2024; Stangeland et al., 2025).

• Mental status changes: Lethargy to coma
• Pupils: Pinpoint
• Respirations: Slow to severely depressed
• Blood pressure/heart rate: Bradycardia, hypotension
• Naloxone response: Yes for opioids, no for barbiturates and toxic alcohols

Physiologic opposites: Both toxidromes are dramatic and potentially lethal but can be recognized quickly and are easy to remember because of the classic "wet vs. dry" presentations (Delaney et al., 2022; Stangeland et al., 2025).

The modern overdose patient often presents with a toxidrome that is caused by more than one substance. The concurrent use of fentanyl-laced stimulants and opioid-benzodiazepine combinations or the use of counterfeit pills containing more than one synthetic is common. These result in mixed or atypical toxidromes that can be difficult to recognize (Amaducci et al., 2023; Delaney et al., 2022; Edinoff et al., 2023; Gallo & Hulse, 2021; Nadal-Gratacós et al., 2024; NIDA, 2024; Stangeland et al., 2025).

Patterns to watch out for:

Point-of-care tests (POCT) are used to provide immediate information at the bedside, and in poisoning scenarios, can identify life-threatening abnormalities long before more definitive results are available from the lab.

Screening is designed to detect the presence (not necessarily the amount) of drugs or poisons in blood or urine. Most hospitals use immunoassay panels, which react to characteristic chemical structures.

These screens are useful, but they have some important limitations:

• They can only detect substances included in the panel.
• They can give false positives or false negatives.
• Concentrations rarely correlate with the severity of illness.

Therefore, tox screens should support, but never replace, clinical judgment.

Limitations:

• Fentanyl, methadone, tramadol, and designer synthetics often escape detection.
• Immunoassays can cross-react (diphenhydramine falsely positive for TCAs).
• Urine screens lag behind blood levels and reflect past use rather than acute toxicity.

Confirmatory testing by gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS) precisely identifies specific compounds and their concentrations. When immunoassay results are unexpected or require documentation, confirmatory testing by GC-MS or LC-MS/MS is indicated.

Confirmatory testing is indicated when:

• The screen is positive but clinically inconsistent.
• Legal or occupational implications exist.
• Medical management depends on exact identification (digoxin level, for example).

Because these tests can take hours to days, they do not guide emergent management but are invaluable for documentation, public health tracking, and, sometimes, refining long-term care.

Some toxins have therapeutic or toxic ranges and should be quantified:

(ECG): An ECG may provide indirect evidence of poisoning. Nurses should obtain a baseline ECG and repeat when new symptoms develop or after antidote administration (Kariisa et al., 2023; Stangeland et al., 2025).

• Prolonged QRS (> 100 ms): TCAs, quinidine.
• QT prolongation: Antipsychotics, macrolides, certain antihistamines.
• Bradyarrhythmia: Digoxin, beta-blockers.
• Tachyarrhythmia: Cocaine, amphetamines.

Imaging: Diagnostic imaging is rarely diagnostic of poisoning per se, but may detect important complications.

• Chest X-ray: Aspiration, pulmonary edema.
• Abdominal X-ray: Radiopaque pills (iron, lithium, enteric-coated medications).
• CT scan of head: Intracranial pathology, if altered mental status cannot be explained by other causes.

Bedside Ultrasound: Focused cardiac ultrasound may be used to assess ejection fraction (EF) in patients with beta-blocker or calcium channel blocker toxicity and to guide fluid therapy.

Since 2022, the growing prevalence of high-potency synthetic opioids such as fentanyl, carfentanil, and nitazenes has necessitated more aggressive naloxone dosing and, in some cases, continuous infusion (Amaducci et al., 2023; Kariisa et al., 2023; Stangeland et al., 2025).

These drugs have tighter binding to opioid receptors and can remain in the body for hours longer than naloxone, which can wear off, leaving residual respiratory depression (Amaducci et al., 2023; Kariisa et al., 2023; Stangeland et al., 2025).

Mechanism of Action

Naloxone is a competitive opioid receptor antagonist that displaces the effects of opioids on the brainstem respiratory center. It works very quickly, within 1–2 minutes IV or 3–5 minutes IN, but has a shorter duration (30–90 minutes) than most opioids, especially long-acting or synthetic preparations (Amaducci et al., 2023; Kariisa et al., 2023; Stangeland et al., 2025).

Nursing Considerations

• Airway first: Bag-valve-mask ventilate the patient before and after naloxone administration as needed (Amaducci et al., 2023; Kariisa et al., 2023).
• Titrate, do not shock: Wait for and avoid abrupt awakening and agitation; titrate dose to adequate ventilation.
• Close monitoring: Pulse oximetry, ECG, and level of consciousness every 5–10 minutes.
• Withdrawal signs: Watch for and treat opioid withdrawal, restlessness, vomiting, tachycardia, or hypertension in dependent patients (Amaducci et al., 2023; Stangeland et al., 2025).
• Education: Encourage acceptance of take-home naloxone kits and harm-reduction counseling at discharge in overdose survivors (Amaducci et al., 2023; Kariisa et al., 2023).

The mainstay of management for toxicity or overdose is supportive care and airway management, not reversal (Gallo & Hulse, 2021; NIDA, 2024). However, in certain cases, flumazenil remains an antidote for some.

Flumazenil can reliably reverse sedation after procedural or therapeutic anesthesia or from accidental ingestion in pediatric patients, but is very rarely indicated for the management of benzodiazepine overdose due to the risk of precipitating seizures in benzodiazepine-dependent patients and mixed overdoses.

Mechanism of Action

It is a competitive benzodiazepine receptor antagonist (Gallo & Hulse, 2021; NIDA, 2024). Flumazenil blocks the binding of benzodiazepines at the GABA receptor, reversing sedation (Gallo & Hulse, 2021; NIDA, 2024). Treatment has a rapid onset (1–2 minutes IV); duration of effect is 30–60 minutes.

Indications

Indications include the following (Gallo & Hulse, 2021; NIDA, 2024):

• Iatrogenic oversedation, e.g., post-procedure with midazolam.
• Accidental pediatric ingestion of pure benzodiazepine.
• Documented, isolated benzodiazepine overdose without chronic dependence and no co-ingestants or other contraindications.

Contraindications

• Mixed overdose, especially with TCAs, stimulants, or other proconvulsant drugs (Delaney et al., 2022; Nadal-Gratacós et al., 2024).
• Chronic use of benzodiazepines (Gallo & Hulse, 2021; NIDA, 2024).
• History of seizure disorder or head injury.
• Unknown ingestion with no clear history and possible proconvulsant ingestion.

Nursing Considerations

• Confirm availability of airway management resources and seizure medications before administering.
• Provide continuous cardiac and neurologic monitoring.
• Document indication, total dose, and clinical response.
• Prepare for re-sedation as the flumazenil wears off.
• Notify the provider or Poison Control if a seizure or arrhythmia occurs.

The cornerstones of treatment for organophosphate or carbamate poisoning (cholinergic crisis) are physostigmine, atropine, and pralidoxime. In these poisonings, an overabundance of acetylcholine causes overstimulation of the muscarinic and nicotinic receptors, leading to copious secretions, bradycardia, and respiratory failure.

Nursing Priorities:

• Protect staff: decontaminate before handling clothing or skin.
• Keep atropine available for cholinergic crisis as well as for physostigmine reversal.
• Continuous monitoring of ECG, oxygen saturation, secretions, and muscle tone.
• Document time, dose, and patient response to inform titration.
• Collaborate with Poison Control and respiratory therapy as needed.

Activated charcoal is still a mainstay of gastrointestinal decontamination, but its use is now more limited and selective.

Mechanism of Action

Charcoal is a porous adsorbent material that binds many organic substances on its surface. The charcoal/toxin complex is too large to be absorbed and is excreted in the stool.

Indications

• Ingestion of a potentially toxic amount of a charcoal-binding substance.
• Patient is within one hour of ingestion (sometimes later for delayed-release products).
• Airway protected, or the patient is alert and/or cooperative.

Contraindications

• Unprotected airway or altered mental status in an un-intubated patient.
• Ingestion of caustic or hydrocarbon substances.
• Ileus, obstruction, or gastrointestinal perforation.

Dosing

• Adult: 1 G/kg (generally 50–100 G).
• Pediatric: 1 G/kg (maximum 50 G).
• Administer as a slurry (1:4 charcoal-to-water ratio).

Multiple-dose activated charcoal (MDAC) is used to increase the elimination of substances subject to enterohepatic recirculation, such as carbamazepine, phenobarbital, and theophylline.

Protocol: 25–50 G every 4 hours (adults). While on MDAC, monitor closely for changes in bowel function and the risk of aspiration.

Airway management is the single most important step in the management of the poisoned patient. Intubate before the patient arrests, not after. Once the airway is lost, it is much harder to regain in a patient with secretions, vomiting, or CNS depression.

• Indications for mechanical ventilation include:
• Inability to protect the airway (GCS ≤ 8).
• Recurrent or severe hypoventilation (respiratory rate < 8, or pCO₂ > 60 millimeters of mercury [mmHg]).
• Persistent hypoxemia despite oxygen therapy.
• Severe acidosis requiring controlled ventilation.
• Anticipated clinical deterioration (e.g., delayed respiratory depression after methadone or clonidine).

Roles during Intubation

• Prepare suction, bag-valve-mask, and airway adjuncts before administration of medications.
• Ensure equipment and cuff sizes are correct for an appropriate fit.
• Continuously monitor ECG, SpO₂, and end-tidal CO₂.
• Anticipate hypotension after induction, especially if the cardiovascular system is already depressed by the overdose (sedatives, calcium channel blockers).
• Document time, medications, and immediate response.

Ventilator Management Considerations

Ventilation strategies are supportive, not disease-specific. There are a few toxins that can directly affect respiratory drive or patterns.

The most common causes of cardiovascular compromise from overdose include:

• Myocardial depression: Beta-blockers, calcium channel blockers, TCAs.
• Vasodilation: Sedatives, opioids, nitrates, antipsychotics (Amaducci et al., 2023; Stangeland et al., 2025).
• Arrhythmias: TCAs, digoxin, cocaine, amphetamines.

Monitor:

• Continuous ECG.
• Blood pressure (ideally with an arterial line if unstable).
• Urine output and skin perfusion.

Stepwise Nursing Approach

1. Fluids first:
   • Administer isotonic crystalloids (normal saline or lactated Ringer's).
   • Reassess perfusion after each bolus (20 mL/kg typical starting point).
2. Vasopressors:
   • Norepinephrine is first-line for persistent hypotension.
   • Epinephrine may be particularly helpful in bradycardic, beta-blocked, or calcium channel–blocked patients.
   • Avoid dopamine-unpredictable effects, which may worsen tachyarrhythmias.
3. Specific supportive therapies:
   • Sodium bicarbonate for QRS widening caused by TCAs.
   • High-dose insulin euglycemia therapy for beta-blocker or calcium channel blocker toxicity (requires close glucose/potassium monitoring).
   • Intravenous lipid emulsion (ILE) as rescue for lipophilic drug overdose (bupivacaine, propranolol).
4. Monitor and reassess continuously:
   • Vital signs every 5–15 minutes in unstable patients.
   • Trend ECG changes, lactate, and urine output.

Stimulant drugs, such as cocaine, amphetamines, MDMA (ecstasy), bath salts, and synthetic cathinones, can cause life-threatening hyperthermia (Delaney et al., 2022; Nadal-Gratacós et al., 2024). Current practice includes the use of benzodiazepines to reduce agitation and muscle activity, preventing further heat generation (Gallo & Hulse, 2021; NIDA, 2024). It is also important to avoid antipyretics, as they are ineffective for hyperthermia caused by stimulant or serotonin toxicity (Delaney et al., 2022; Nadal-Gratacós et al., 2024).

Hyperthermia results from:

• Increased muscular activity (tremors, agitation, seizures).
• Direct stimulation of the hypothalamus (impaired heat regulation).
• Environmental factors (hot surroundings, dehydration).

Temperatures > 104°F (40°C) can precipitate rhabdomyolysis, renal failure, disseminated intravascular coagulation, and death.

Clinical features include:

• Elevated core temperature.
• Diaphoresis (progressive anhidrosis/dry skin with exhaustion).
• Tachycardia, hypertension, confusion, seizures.
• Myoglobinuria (dark urine).

Shivering should be managed.

Shivering further increases temperature and physiologic workload. Treat with (Gallo & Hulse, 2021; NIDA, 2024):

• Benzodiazepines (diazepam or lorazepam).
• If refractory, use a short-acting muscle relaxant (vecuronium) in intubated patients.

On the other hand, overdoses from sedatives or opioids frequently result in hypothermia as a result of CNS depression and immobilization (Amaducci et al., 2023; Stangeland et al., 2025).

Nursing interventions include:

• Warm blankets, Bair Hugger, or radiant heat.
• Warmed IV fluids and humidified oxygen.
• Monitor temperature frequently to prevent rebound hyperthermia.

Seizures in toxicologic emergencies are a sign of significant CNS involvement and are medical emergencies that should be treated rapidly. Seizures in mixed overdoses can often be multifactorial in mechanism and may be more refractory to treatment.

Common causes include (Gallo & Hulse, 2021; NIDA, 2024):

• TCAs
• Bupropion
• Isoniazid (INH)
• Theophylline
• Cocaine, amphetamines
• Withdrawal from alcohol or benzodiazepines 
• Hypoxia or metabolic derangements

Stepwise Nursing and Medical Approach 

An effective approach includes the following (Gallo & Hulse, 2021; NIDA, 2024):

1. Airway and safety: Protect the airway; prevent injury. Turn the patient on their side, pad bedrails, and prepare suction and oxygen.
2. Check glucose: If hypoglycemia (blood glucose < 70 mg/dL), treat with 25–50 mL D50 IV; administer thiamine if malnourished.
3. First line: Lorazepam 2–4 mg IV q five minutes (alternatively diazepam 5–10 mg IV). Repeat as necessary and monitor respirations.
4. Second line: Phenobarbital 15–20 mg/kg IV. This can be used for INH toxicity or when seizures are refractory to benzodiazepines.
5. Third line: Propofol or midazolam Infusion. This is often given in the intensive care unit (ICU) for status epilepticus. It should only be done when airway control and hemodynamic monitoring can be provided.
6. Adjunct: Pyridoxine (Vit B₆) for isoniazid toxicity. Dose = amount of INH ingested (gram-for-gram), or 5 G IV if the amount is unknown.

Clinical considerations include:

• Avoid phenytoin-no benefit and may even worsen seizures in TCA or theophylline toxicity.
• Correct electrolyte imbalances (Na⁺, Ca²⁺, Mg²⁺).
• Treat for hyperthermia as appropriate.
• Continue cardiac monitoring, as tachyarrhythmias are common.

Ongoing Monitoring and Supportive Care

Post-stabilization, ensure ongoing support to prevent complications and identify decompensation. Delivering care to these patients is, by default, a team sport. Toxicology nurses may lead but cannot manage complex overdoses alone.

Responsibilities include:

• Continued reassessment (vital signs, LOC, pupils, skin temperature) every 15–30 minutes until fully stable.
• Fluid balance maintenance and ensuring urine output of ≥ 0.5 mL/kg/hr.
• Labs: Repeat ABGs, electrolytes, and lactate to track metabolic trends.
• Nutrition: Consider early enteral feeding when stable to promote recovery and maintain gut integrity.
• Psychosocial support: Use nonjudgmental, supportive communication. Involve the mental health/behavioral health team early for intentional ingestions.
• Family education: Alert family members of the potential for prolonged ventilation and/or neurologic monitoring.

Delivery of ongoing supportive care is a multidisciplinary team effort (Kariisa et al., 2023; Stangeland et al., 2025).

• Respiratory therapy: Optimize ventilator settings, assess readiness for weaning.
• Pharmacy/toxicology: Assist with dosing of antidotes, insulin therapy, or lipid rescue. 
• Critical care physicians: Hemodynamic support with fluids and vasopressors, possibly invasive monitoring.
• Social work/behavioral health: Assist with discharge planning, addiction counseling, and outpatient resources.

Clinical readiness is only part of the story in the current overdose environment; the other part involves policy, regulation, and public health coordination. The rise of synthetic compounds has outpaced traditional drug control frameworks, with new legislative measures and emergency scheduling orders reshaping how healthcare systems respond to evolving overdose trends. Federal and state agencies have also implemented enhanced surveillance and reporting mandates for early detection and community protection. The following section reviews recent legislative and public health developments. This includes DEA scheduling of nitazenes and nonbenzodiazepine sedatives, the National Xylazine Response Plan, and new state-level overdose reporting requirements. These updates will help professionals stay informed about not only clinical care at the bedside but also the larger systems that govern clinical alerts, education, and prevention (DEA, 2025; Gallo & Hulse, 2021; Gupta et al., 2023; NIDA, 2024; ONDCP, 2023).

The legal and public health landscape surrounding drug overdose response in the United States has evolved dramatically over the past three years. Synthetic substances such as nitazenes, xylazine, and nonbenzodiazepine sedatives have entered the illicit drug market, prompting regulatory agencies to act, sometimes reactively, to control distribution and improve surveillance (Gallo & Hulse, 2021; Gupta et al., 2023; NIDA, 2024; ONDCP, 2023).

For nursing professionals, understanding these updates is crucial not only for policy adherence but for clinical safety and professional accountability. Awareness of newly scheduled substances, state-specific overdose reporting mandates, and the mechanisms for public health alerts ensures that care is timely, coordinated, and in line with national response efforts.

The following section highlights recent policy and public health developments, with an emphasis on their implications for clinical nursing practice, documentation, and patient education.

New DEA Scheduling Orders 

The DEA "schedules" controlled substances listed in the Controlled Substances Act (CSA) to place restrictions on their manufacture, distribution, and possession. New drugs can be "scheduled" temporarily or permanently based on their risk to public health (DEA, 2021).

In 2022, the DEA began issuing temporary emergency scheduling orders to the growing list of nitazenes and nonbenzodiazepine sedative analogs as U.S. overdose deaths began to rise (DEA, 2025; Gallo & Hulse, 2021; NIDA, 2024). Since then, increased scheduling and limitations have been in place to decrease risk.

Nonbenzodiazepine Sedative Analogues 

Description: These are designer benzodiazepine analogs that are not approved for medical use in the United States and are often marketed in counterfeit pills as "Xanax" or "Valium" (Gallo & Hulse, 2021; NIDA, 2024). They are more potent and longer-acting than benzodiazepines that are prescribed in the United States. May not reliably reverse with flumazenil and may cause more prolonged sedation/respiratory depression when combined with opioids. They are frequently missed on routine urine drug screens and often need to be sent for confirmatory GC-MS (Amaducci et al., 2023; Gallo & Hulse, 2021; NIDA, 2024; Stangeland et al., 2025).

Xylazine ("Tranq")

As xylazine contaminated illicit fentanyl supply chains during 2022–2023, the White House ONDCP announced xylazine as a "major emerging threat" in 2023. The National Xylazine Response Plan (NXRP) was released, bringing together federal, state, and local initiatives (Gupta et al., 2023; ONDCP, 2023).

Numerous state laws and regulations have been enacted requiring hospitals and other healthcare facilities to report all overdoses and toxicology-confirmed deaths to their state health departments.

These state-level efforts advance timely, actionable data, inform resource distribution, and target regional surges of newly emerging substances. This list is not all-inclusive.

Brief, actionable notifications are released by public health agencies, such as the CDC, DEA, or local/state health departments, when a new substance or an emerging pattern of use is present in communities and poses a safety risk. The number and clinical specificity of public health alerts have rapidly increased, and alerts are often sent directly to EDs to speed distribution.